Neoss Launches NeoGenix XP™

Safe and Clinically Proven Natural Bone Substitute

Following the successful and well-received Allograft line, Neoss is excited to announce the addition of NeoGenix XP™ this autumn to our existing product portfolio.

NeoGenix XP™ is a safe and clinically proven natural bone substitute, that closer resembles natural bone than those of synthetic materials, such as hydroxyapatite or tricalcium phosphate.

Surface roughness affects cellular response, enhancing cell adhesion and proliferation and possibly other markers of expression of cell phenotype, like production of collagen type I, osteocalcin, extracellular matrix, and mineralized material.

“Being a strong partner to our customers has always been important and offering more in terms of total package solutions. NeoGenix XP™ is an important addition to this and strengthens not only the bone regeneration portfolio but will allow us to serve our customer even better!” —Dr Robert Gottlander, Neoss CEO

This exciting product line will add new dimensions to Neoss existing Bone Regeneration offering, providing an enhanced offering of Bone materials and membranes.

Neoss maintains its clear focus on innovation and has a continuous plan of new market leading product solutions that will be presented over the next few years. All with the same target of introducing smart products that are intuitively easy to use with Intelligent Simplicity.

More here.

 

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.